Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274152 | 1.00 | ALOX5 (0.39) | ALOX5GRM5MAP4K1MEN1NPC1 | |
| SCHEMBL2272864 | 0.87 | ALOX5 (0.40) | ALOX5MEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL2272858 | 0.87 | ALOX5 (0.40) | ALOX5MEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL2837846 | 0.86 | ALOX5 (0.38) | ALOX5MEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL726726 | 0.86 | ALOX5 (0.39) | ALOX5MEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL726658 | 0.83 | IMPDH2 (0.38) | GRM5IMPDH2 | |
| SCHEMBL1254826 | 0.81 | ALOX5 (0.39) | ALOX5MEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL1254829 | 0.81 | ALOX5 (0.39) | ALOX5MEN1NPC1ALDH1A1RAB9A | |
| SCHEMBL19118662 | 0.81 | ALOX5 (0.38) | ALOX5 | |
| SCHEMBL726943 | 0.80 | ALOX5 (0.39) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846819-B1 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-01-25 | — | — | US | claimed |
| EP-1226138-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-12-29 | — | — | EP | claimed |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | DEBIOPHARM INTERNATIONAL SA (CH) | 2013-10-24 | — | — | US | disclosed |
| US-8173646-B2 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2012-05-08 | — | — | US | disclosed |
| US-20110190283-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2011-08-04 | — | — | US | disclosed |
| US-7790716-B2 | fatty acid biosynthesis inhibitors such as E)-3-(6-aminopyridin-3-yl)-N-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)acrylamide, used fro the treatment of bacterial infections; antibiotics | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20090275572-A1 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7557125-B2 | Fab I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2009-07-07 | — | — | US | disclosed |
| US-7524843-B2 | N-methyl-N-(1-methyl-1H-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide as an enzyme inhibitor for both Fab I and Fab K which are used in the biosynthesis of fatty acids; enoyl-acyl-carrier protein renamed Fab 1; bactericides; fungicides; Staphylococcus aureus; antibiotics | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2009-04-28 | — | — | US | disclosed |
| US-20080125423-A1 | Fab I Inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2008-05-29 | — | — | US | disclosed |
| US-20050250810-A1 | FAB I inhibitors | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-11-10 | — | — | US | disclosed |
| EP-1226138-B1 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2004-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250810-A1 | FAB I inhibitors | SERPINB1, TFPI, TFPI2 | ALOX5 2861/4885GRM5 4738/4885MAP4K1 2506/4885 |
| US-20130281442-A1 | Compounds for Treatment of Bovine Mastitis | LPO, MPO, MMP8 | ALOX5 346/4885GRM5 1310/4885MAP4K1 2902/4885 |
| US-20090275572-A1 | FAB I INHIBITORS | SERPINB1, TFPI, TFPI2 | ALOX5 2861/4885GRM5 4738/4885MAP4K1 2506/4885 |
| US-20080125423-A1 | Fab I Inhibitors | SERPINB1, TFPI, TFPI2 | ALOX5 2861/4885GRM5 4738/4885MAP4K1 2506/4885 |
| US-20110190283-A1 | Fab I Inhibitors | SERPINB1, TFPI, TFPI2 | ALOX5 2861/4885GRM5 4738/4885MAP4K1 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.